WZWenxiu Zhang

Wenxiu Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wenxiu Zhang has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Dazheng Li

    Department of Urology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong Province, China

    1 shared publication
  • Jianning Wang

    Department of Urology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong Province, China

    1 shared publication
  • Na Li

    Mass Spectrometry Research Institute, Beijing Gobroad Hospital, Beijing, China

    1 shared publication
  • Tianyi Wang

    Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, China

    1 shared publication
  • Wenzhi Du

    Department of Urology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China; Medical Integration and Practice Center, Shandong University, Jinan, Shandong, 17 250012 China

    1 shared publication
  • Yong Zeng

    Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University

    1 shared publication

Latest Publications

  • Open Access

    Unveiling novel drug targets for atherosclerosis: A Mendelian randomization analysis

    by Wenzhi Du, Dazheng Li, Na Li, Wenxiu Zhang, Jianning Wang, Tianyi Wang, Yong Zeng

    Atherosclerosis is a leading cause of cardiovascular diseases, necessitating the identification of novel therapeutic targets. By utilizing Mendelian randomization, the aim is to identify potential drug targets for the treatment of atherosclerosis. Using results from genomewide association studies and protein quantitative trait loci data, we genetically identified causal effects of levels of several circulating proteins on atherosclerosis risk, validated using multiple statistical approaches, and identified promising drug targets. These findings demonstrated promising targets worthy of further clinical study, especially lipoprotein (a) and proprotein convertase subtilisin/kexin type 9.